HpaII Polymerase Chain Reaction Restriction Fragment Length Polymorphism in the Human CD19 Gene on 16p11

• Published in: Human heredity Vol. 48; no. 4; pp. 230 - 231
• Main Authors: Thunberg, U., Gidlöf, C., Bånghagen, M., Sällström, J.F., Sundström, C., Tötterman, T.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.07.1998; Karger
• Subjects: Antigens, CD19 - genetics; B lymphocyte; Biological and medical sciences; CD19; Chromosomes, Human, Pair 16; Classical genetics, quantitative genetics, hybrids; Deoxyribonuclease HpaII; Exons - genetics; Fundamental and applied biological sciences. Psychology; Genetics of eukaryotes. Biological and molecular evolution; Human; Humans; MEDICIN; MEDICINE; Molecular Sequence Data; Mutation Report; Polymerase Chain Reaction - methods; Polymorphism; Polymorphism, Restriction Fragment Length; B lymphocyte; CD19; Polymorphism; Genetic mapping; Human; Restriction fragment length polymorphism; Chromosome E16; Gene frequency; Gene; Genetic marker; B-Lymphocyte
• ISSN: 0001-5652; 1423-0062; 1423-0062
• DOI: 10.1159/000022806

Sorry, there is no abstract. Read the first few lines of the text instead! The CD19 is a 95-kD transmembrane pan-B lymphocyte marker. It serves as a cell surface response regulator that establishes signaling thresholds critical for B lymphocyte development, activation and proliferation. CD19 enhances membrane IgM signaling and is required for B lymphocyte antibody responses to T-dependent antigens . Polymerase chain reaction (PCR) restriction fragment length polymorphism analysis revealed a polymorphic site in exon 4 of CD19 at proline 235, without changing the amino acid with an observed heterozygosity of 0.42. Thus the biological significance of this polymorphic site remains unknown.